Health‐economic analysis: cost‐effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults

Abstract

SUMMARY BackgroundInfliximab has been shown to be efficacious in moderate-to-severe Crohn's disease (CD).

Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States

“…Two recent studies from the United Kingdom evaluated the cost-effectiveness of infliximab therapy in CD and UC. Lindsay et al 39 analyzed a Markov model of hypothetical 60 kg adult CD patients treated with infliximab (5 mg/kg) every 8 weeks. Infliximab was cost-effective for both active luminal and fistulizing disease.…”

Racial disparities in utilization of specialist care and medications in inflammatory bowel disease

“…These biologic agents have additionally resulted in lower hospitalizations and surgery when judiciously implemented (2)(3)(4)(5)(6)(7). Though biologics are considerably more expensive than other medications in the IBD armamentarium, they have been shown to be cost-effective when appropriately indicated (8)(9)(10)(11).…”

A model of the long‐term cost effectiveness of scheduled maintenance treatment with infliximab for moderate‐to‐severe ulcerative colitis

“…This suggests patient weight to be a less important consideration in UC compared with other indications of IFX. 7 In conclusion, IFX is an effective and well-tolerated therapy for the management of moderate-to-severe UC patients and provides significant clinical benefit over standard care. This economic analysis demonstrated that this clinical and quality of life benefit justifies the additional costs to NHS in England and Wales, thus making IFX SMT a cost-effective treatment option.…”

“…A recent cost effectiveness analysis demonstrated IFX SMT to be cost effective in moderate-severe Crohn's patients. 7 To date, however, no study has estimated the cost effectiveness of IFX in UC. The present economic evaluation was performed to assess the cost effectiveness of IFX SMT at the licensed dose of 5 mg ⁄ kg compared with standard care without IFX, for the treatment of patients with moderate-severe chronic UC.…”